content_image/65919.jpg
<img src='content_image/65919.jpg'>

The studies demonstrated a statistically significant difference in the results of treated patients compared to those on placebo. Clinical improvement with oral tazarotene was seen as early as four weeks, with significant improvement seen within eight weeks of treatment. Based on those results, we submitted a new drug application to the FDA for oral tazarotene for psoriasis in November 2003. 

We also have seen promising Phase II data for oral tazarotene for the treatment of acne and will seek a global devel- opment partner for the Phase III clinical trials. In addition, we currently intend to out-license the tazarotene molecule for the treatment of psoriasis outside North America. 

In the meantime, a topical retinoid of choice for physicians managing psoriasis and acne is TAZORAC (tazarotene cream 0.05% and 0.1% and tazarotene gel 0.05% and 0.1%), which was specifically designed to deliver effective relief. Head-to-head clinical studies comparing TAZORAC to various competitive products have demonstrated its potency. These results demonstrate why patients trust TAZORAC to unlock the challenges of their skin condition and restore their confidence to participate in life’s daily activities. 

## wayne orme and psoriasis 

A rodeo cowboy who has had severe psoriasis for the last 30 of his 63 years, Wayne Orme says, “You cannot live a nor- mal life [with the condition]. People stare at you. When you have guests, you’re constantly hiding. And if you’re single like I am, well, dating is not worth the embarrassment.” 

According to the National Psoriasis Foundation, 4.5 million Americans have the genetic autoimmune disease. Typically appearing between the ages of 15 and 35, psoriasis is characterized by plaques that occur when the patient’s body speeds up the skin-producing cells. Patients in Allergan’s 

clinical trials were required to have plaques covering more than 20 percent of their bodies. To put that in perspective, 1 percent of a person’s body is roughly equal to the size of his or her palm. 

Allergan’s TAZORAC (tazarotene cream 0.05% and 0.1% and tazarotene gel 0.05% and 0.1%), a receptor-selective retinoid cream, has been used to treat psoriasis and acne since 1997. In 2003, the Company completed its Phase III clinical trials of an oral tazarotene compound for psoriasis and filed a new drug application with the FDA. 

